Biotechnology - UK, Oncology

Filter

Current filters:

UKOncology

Popular Filters

NetScientific invests in PDS Biotechnology

NetScientific invests in PDS Biotechnology

15-12-2014

UK-based life sciences investor NetScientific has made an undisclosed investment in privately-held US…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsNetScientificOncologyPDS BiotechnologyUK

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

04-11-2014

Anglo-Swedish drug major AstraZeneca and US health care giant Johnson & Johnson’s Europe-based subsidiary…

AstraZenecaBiotechnologyImbruvicaJanssenMEDI4736OncologyPharmacyclicsResearchUK

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

16-10-2014

In preliminary draft guidance issued this morning the UK health costs watchdog the National Institute…

BiotechnologyDendreonOncologyPricingProvengeRegulationUK

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

15-10-2014

UK medical costs watchdog the National Institute for Health and Care Excellence (NICE) has issued preliminary…

BiotechnologyCelgene Corp.ImnovidOncologyPricingRegulationUK

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

02-10-2014

UK biotech firm Oxford BioTherapeutics and family-owned Italian Berlin Chemie/Menarini Group have designated…

BiotechnologyItalyMenariniOncologyOxford BioTherapeuticsResearchUK

AstraZeneca's Medimmune to collaborate on new oncology biologics lab with Cancer Research UK

AstraZeneca's Medimmune to collaborate on new oncology biologics lab with Cancer Research UK

25-09-2014

Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCancer Research TechnologyCancer Research UKMedImmuneOncologyResearchUK

Adaptimmune completes $104 million round of financing to advance cancer therapies

Adaptimmune completes $104 million round of financing to advance cancer therapies

25-09-2014

Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease,…

AdaptimmuneBiotechnologyFinancialGlaxoSmithKlineOncologyUK

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

24-09-2014

The UK’s drug watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgene Corp.OncologyPricingRegulationRevlimidUK

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

17-09-2014

The UK’s Department of Health announced that DCVax-L, the dendritic cell-based vaccine from US company…

BiotechnologyDCVaxNorthwest BiotherapeuticsOncologyRegulationUK

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

15-09-2014

The charity Cancer Research UK and its commercialization arm Cancer Research Technology (CRT), have reached…

Asterias BiotherapeuticsBiotechnologyBioTimeCancer Research TechnologyLicensingOncologyResearchUKVaccines

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

09-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published new draft…

AbraxaneBiotechnologyCelgene Corp.OncologyPaclitaxelPricingRegulationUK

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

NICE U-turn on Celgene’s Revlimid for myelodysplastic syndromes

20-08-2014

UK drugs watch dog the National Institute for Health and Care Excellence (NICE) has issued final draft…

BiotechnologyCelgene Corp.Myelodysplastic syndromesOncologyPricingRegulationRevlimidUK

Immunocore and Eli Lilly sign $25 million collaboration

Immunocore and Eli Lilly sign $25 million collaboration

16-07-2014

UK-based biotech firm Immunocore and US drug major Eli Lilly today announced they have entered into a…

BiotechnologyEli LillyImmunocoreImmunologyLicensingLillyOncologyUKUSA

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

08-07-2014

The Scottish Medicines Consortium (SMC) has issued guidance on Anglo-Swedish drug major AstraZeneca’s…

AstraZenecaBiotechnologydapagliflozinDiabetesMabTheraOncologyRocheUK

NICE draft guidance negative on Celgene’s Revlimid

20-05-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgeneOncologyPricingRegulationRevlimidUK

Angle appointments new Scientific Adviser

Angle appointments new Scientific Adviser

26-03-2014

Angle (AIM:AGL), the specialist medtech company, has appointed Clive Stanway as a Scientific Adviser…

AngleBiotechnologyBoardroomCancer Research TechnologyOncologyUK

NICE says better information needed on Celgene’s MM drug

NICE says better information needed on Celgene’s MM drug

14-03-2014

The UK drugs watchdog, the National Institute for Health and care Excellence (NICE) says that, based…

BiotechnologyCelgeneNorthern EuropeOncologyPricingRegulationRevlimidUK

Cell Thera’s NHL drug Pixuvri gets backing from UK’s NICE

27-02-2014

US biotech firm Cell Therapeutics has received positive news from the UK’s drugs watchdog for use of…

BiotechnologyCell TherapeuticsNorthern EuropeOncologyPixuvriPricingRegulationUK

Nuevolution signs international deal to screen potential cancer drugs using DNA tags

Nuevolution signs international deal to screen potential cancer drugs using DNA tags

22-01-2014

An innovative screening technology that tags compounds with unique strands of DNA will be used to assess…

BiotechnologyDenmarkNuevolutionOncologyResearchUK

Back to top